ZYBERNO
Stock Report
Updated Aug 22, 2026

LakeShore Biopharma Co., Ltd (LSBCF)

Healthcare • OTC

$0.07

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
3.0/100
POOR BUSINESS
LakeShore Biopharma Co., Ltd (LSBCF) scores 3/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):AVERAGE (0.83x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-5.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

LakeShore Biopharma Co., Ltd (LSBCF) stock report — Zyberno Score 3/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.07
Market Cap:$1.28M

Valuation Multiples (2)

P/B Ratio:0.02x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$109.43M

Price Action & Momentum (1)

% of 52-Week High:5.4%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:26.3%
Fundamental Growth Rate (g):-1.3%

Margin Analysis (1)

Ebitda Margin:-9.2%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.02x
Quick Ratio:0.75x
Cash Ratio:0.03x

Leverage Analysis (3)

Debt To Equity Ttm:0.83x
Debt-to-Equity Ratio:0.83x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-4.86x
Times Interest Earned:-4.86

Capital Structure (4)

Working Capital:2,433,128.00
Cash And Cash Equivalents:3,912,340.00
Long Term Debt:$57.67M
Net Debt:$108.15M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$85.67M
Cost Of Revenue Ttm:$15.01M

Profitability Breakdown (2)

$70.66M-$12.02M

Bottom Line Performance (3)

-$13.93M
Income Before Tax:-$14.06M
Ebitda Ttm:-7,879,243.00

Operating Expenses (5)

Operating Expenses:82,678,293.00
R And D Expense:20,390,779.00
Sga Expense:17,966,588.00
Income Tax Expense:-$131.91K
Interest Expense:2,474,088.30

Expense Ratios (3)

R And D To Revenue Percentage:23.8%
Sga To Revenue Percentage:21.0%
Ebitda Margin:-9.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$190.53M
Current Assets:$117.33M
Ppe Net:57,605,172.00
Goodwill:0.00
Intangible Assets:$10.15M

Liability Structure (4)

Total Liabilities:120,908,943.00
Current Liabilities:114,896,843.00
Long Term Debt:$57.67M
Short Term Debt:$54.39M

Equity & Capital (3)

Equity:$69.62M
Retained Earnings:-$335.39M
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:69,783,067.00
Inventory:31,705,984.00
Accounts Payable:6,903,093.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,888,665.00
C. Cash Flow Analysis

Operating Activities (2)

-$16.85M-$18.62M

Investment Activities (1)

Investing Cash Flow:-$2.37M

Financing Activities (3)

Financing Cash Flow:-$498.86K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:42,103,353.20
Long Term Debt Issuance:$46.64M
Long Term Debt Repayments:$21.71M

Non-Cash Items (1)

Depreciation Amortization Ttm:4,142,139.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.73

Revenue & Cash Per Share (2)

Sales Per Share Ttm:4.47
Operating Cash Flow Per Share:-$0.88

Book Value & Capital (2)

Book Value Per Share:$3.63
Cash Per Share:0.20

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.45x
Working Capital Turnover Ttm:35.21x

Receivables Management (2)

Receivables Turnover Ttm:1.23x
Days Sales Outstanding Ttm:297.31

Inventory Management (2)

Inventory Turnover Ttm:0.47x
Days Inventory Outstanding Ttm:770.80

Payables & Cash Cycle (2)

Days Payable Outstanding:167.82
Cash Conversion Cycle:900.29
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:26.3%
Fundamental Growth Rate (g):-1.3%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:LSBCF
Company Name:LakeShore Biopharma Co., Ltd
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:China

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:19.16M
Shares Outstanding Basic:19.16M
Shares Outstanding Diluted:19.16M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-22 10:45:42 UTC
Data Timestamp:2026-08-22T10:45:42.331628
Scroll to Top